• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Lefkowitz Steven W exercised 20,000 shares at a strike of $4.03, increasing direct ownership by 20% to 120,498 units (SEC Form 4)

    4/3/25 4:30:05 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRMD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Lefkowitz Steven W

    (Last) (First) (Middle)
    C/O CORMEDIX INC.,
    300 CONNELL DRIVE, SUITE 4200

    (Street)
    BERKELEY HEIGHTS NJ 07922

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CorMedix Inc. [ CRMD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    04/02/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 04/02/2025 M 20,000 A $4.03 120,498(1) D
    Common Stock 30,152 I(2) Wade Capital Corporation Money Purchase Plan
    Common Stock 2,000 I Reporting Person's Wife
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy Common Stock) $4.03 04/02/2025 M 20,000 (3) 02/22/2032 Common Stock 20,000 $0.00 0 D
    Explanation of Responses:
    1. The Reporting Person acquired stock through the exercise of options granted on 02/22/2022. The Reporting Person paid the exercise price in cash. No sales of stock were made.
    2. The Reporting Person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which the Reporting Person has voting and investment control).
    3. These stock options, representing a right to purchase 20,000 shares of Common Stock, were granted on 02/22/2022. These stock options are fully vested.
    /s/ Steven W. Lefkowitz 04/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CRMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRMD

    DatePrice TargetRatingAnalyst
    3/7/2025$18.00Outperform
    Leerink Partners
    1/13/2025$15.00Buy
    D. Boral Capital
    8/26/2024$13.00Buy
    Rodman & Renshaw
    8/10/2023$6.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $CRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lefkowitz Steven W exercised 20,000 shares at a strike of $4.03, increasing direct ownership by 20% to 120,498 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      4/3/25 4:30:05 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Todisco Joseph exercised 59,170 shares at a strike of $3.38, increasing direct ownership by 13% to 530,721 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      4/2/25 7:00:03 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Todisco Joseph was granted 187,500 shares and covered exercise/tax liability with 23,977 shares, increasing direct ownership by 53% to 471,551 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      1/22/25 9:11:40 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Commercial Officer Mistry Erin bought $14,985 worth of shares (1,500 units at $9.99), increasing direct ownership by 3% to 52,011 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      12/13/24 4:15:22 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Todisco Joseph bought $50,718 worth of shares (13,561 units at $3.74), increasing direct ownership by 4% to 352,839 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      3/14/24 8:45:21 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dunton Alan W bought $20,250 worth of shares (6,000 units at $3.38), increasing direct ownership by 65% to 15,250 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      12/18/23 4:47:41 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 17, 2023 - FDA Roundup: November 17, 2023

      For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation

      11/17/23 4:18:44 PM ET
      $BMY
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for DEFENCATH issued to CORMEDIX INC

      Submission status for CORMEDIX INC's drug DEFENCATH (ORIG-1) with active ingredient TAUROLIDINE AND HEPARIN SODIUM has changed to 'Approval' on 11/15/2023. Application Category: NDA, Application Number: 214520, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

      11/15/23 9:53:06 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Cormedix with a new price target

      Leerink Partners initiated coverage of Cormedix with a rating of Outperform and set a new price target of $18.00

      3/7/25 7:21:39 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • D. Boral Capital initiated coverage on Cormedix with a new price target

      D. Boral Capital initiated coverage of Cormedix with a rating of Buy and set a new price target of $15.00

      1/13/25 8:29:07 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Cormedix with a new price target

      Rodman & Renshaw initiated coverage of Cormedix with a rating of Buy and set a new price target of $13.00

      8/26/24 7:31:35 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    SEC Filings

    See more
    • CorMedix Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - CorMedix Inc. (0001410098) (Filer)

      6/25/25 6:07:09 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CorMedix Inc. (0001410098) (Filer)

      6/23/25 7:51:56 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by CorMedix Inc.

      10-Q - CorMedix Inc. (0001410098) (Filer)

      5/6/25 8:32:06 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CorMedix inc. Announces Customer Implementation

      BERKELEY HEIGHTS, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces an update related to its Large Dialysis Organization (LDO) customer and planned implementation in the second half of 2025. CorMedix's LDO customer has commenced ordering and will begin the implementation of DefenCath in its patients. Implementation will initially target at least 50% more patients than previously communicated, with the opportunity for further expansion. In connection with this expanded utilization, CorMedix has amended its existing agr

      6/23/25 7:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference

      BERKELEY HEIGHTS, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the Jefferies Global Healthcare Conference, taking place in New York on June 3 - 5, 2025. Jefferies Global Healthcare ConferenceDate:Thursday, June 5, 2025Time:3:45p.m. EDTFormat:PresentationWebcast:Link About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing it

      5/30/25 8:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. to Participate in the RBC Global Healthcare Conference

      BERKELEY HEIGHTS, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the RBC Capital Markets Global Healthcare Conference, taking place in New York on May 20-21, 2025. RBC Capital Markets Global Healthcare ConferenceDate:Wednesday, May 21, 2025Time:3:05p.m. EDTFormat:Fireside ChatWebcast:Link   About CorMedixCorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused

      5/15/25 8:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care